Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Ardelyx Clear all

Conditions: Hyperphosphatemia, End Stage Renal Disease
Interventions: Tenapanor, Sevelamer Carbonate; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: Not listed
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, California

Conditions: Healthy Volunteers
Interventions: Midazolam, AZD1722, AZD1722 and Midazolam; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions: AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 39
States / cities: Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Healthy Volunteer
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cypress, California

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 111
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more

Conditions: Chronic Idiopathic Constipation (CIC)
Interventions: Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 692 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 109
States / cities: Foley, Alabama • Saraland, Alabama • Chandler, Arizona + 98 more

Conditions: Healthy
Interventions: AZD1722, Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Hyperkalemia
Interventions: RDX013, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Synucleinopathy, Parkinson's Disease
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Cedar Valley Digestive Health Center; Other
Eligibility: 50 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Waterloo, Iowa

Conditions: Hyperphosphatemia
Interventions: Tenapanor, Placebo, Sevelamer Carbonate; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: The Bronx, New York • Winston-Salem, North Carolina

Conditions: Healthy Volunteers Food Interaction Study
Interventions: AZD1722 salt tablet, AZD1722 free base tablet, AZD1722 free base tablet + Omeprazole; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Tenapanor; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 27
States / cities: Foley, Alabama • Anaheim, California • Doral, Florida + 24 more

Conditions: Healthy
Interventions: AZD1722, Renvela; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: RDX5791; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: San Diego, California • Jupiter, Florida • Pinellas Park, Florida + 13 more

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Interventions: Tenapanor; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lauderdale Lakes, Florida

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Tenapanor, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 15 more

Conditions: Hyperkalemia
Interventions: RDX227675, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Healthy Volunteers
Interventions: Treatment A (cefadroxil alone), Treatment B - AZD1722 followed by cefadroxil; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Days to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Constipation Predominant Irritable Bowel Syndrome
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Boulder, Colorado • Greensboro, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Lactation
Interventions: Tenapanor; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Madison, Wisconsin

Conditions: Hyperphosphatemia
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 16
States / cities: Downey, California • Los Angeles, California • Sacramento, California + 13 more

Conditions: IBS, IBS - Irritable Bowel Syndrome
Interventions: Tenapanor; Drug
Lead sponsor: Kyle Staller, MD, MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Tenapanor in Synucleinopathy-Related Constipation

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation